Literature DB >> 3566979

Coronary haemodynamic effects of short-term intravenous administration of gallopamil in patients with stable exertional angina.

S De Servi, M Ferrario, S Ghio, A Mussini, L Angoli, E Bramucci, A Bartoli, E Poma, R Rondanelli, G Specchia.   

Abstract

The effects of short term intravenous administration of gallopamil on coronary haemodynamic variables were studied in 10 patients with stable exertional angina and angiographically confirmed coronary artery disease that affected the proximal portion of the left anterior descending artery. Blood flow in the great cardiac vein was measured by a thermodilution technique, both at rest and during ischaemia induced by atrial pacing, before and after intravenous administration of gallopamil (0.02 mg/kg as a bolus dose given over three minutes, followed by an infusion of 0.0005 mg/kg/min). Gallopamil significantly prolonged the mean (SD) duration of pacing that was tolerated (11 (2.6) vs 14.8 (2.4] min, significantly increased the mean (SD) peak heart rate attained during pacing (142 (15) vs 158 (11) beats/min), and reduced mean (SD) arterial pressure (133 (17) vs 116 (17) mm Hg). There were no changes in mean (SD) blood flow in the great cardiac vein (134.1 (57) vs 112.9 (38) ml/min, mean (SD) anterior regional coronary resistance (1.18 (0.6) vs 1.15 (0.5) mm Hg/ml/min), and mean (SD) anterior regional myocardial oxygen consumption (16.6 (6) vs 13.7 (4) ml/min). These data confirm that gallopamil is an effective antianginal agent and suggest that a reduction of myocardial oxygen demand is the predominant mechanism by which the drug exerts its beneficial effects.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3566979      PMCID: PMC1216417          DOI: 10.1136/hrt.57.3.226

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  13 in total

1.  The effect of diltiazem and propranolol, alone and in combination, on exercise performance and left ventricular function in patients with stable effort angina: a double-blind, randomized, and placebo-controlled study.

Authors:  J Hung; I H Lamb; S J Connolly; K R Jutzy; M L Goris; J S Schroeder
Journal:  Circulation       Date:  1983-09       Impact factor: 29.690

2.  Verapamil therapy in variant angina: assessment by high-fidelity frequency modulated ambulatory ECG.

Authors:  V Bala Subramanian; M W Millar Craig; A B Davies; E B Raftery
Journal:  Am Heart J       Date:  1981-06       Impact factor: 4.749

3.  Effects of nifedipine on coronary hemodynamic findings during exercise in patients with stable exertional angina.

Authors:  G Specchia; S de Servi; C Falcone; L Angoli; A Gavazzi; E Bramucci; A Mussini; M Ferrario; J Salerno; C Montemartini
Journal:  Circulation       Date:  1983-11       Impact factor: 29.690

4.  Randomized double-blind comparison of gallopamil and propranolol in stable angina pectoris.

Authors:  N S Khurmi; M J O'Hara; M J Bowles; V B Subramanian; E B Raftery
Journal:  Am J Cardiol       Date:  1984-03-01       Impact factor: 2.778

5.  In vivo validation of a thermodilution method to determine regional left ventricular blood flow in patients with coronary disease.

Authors:  C J Pepine; J Mehta; W W Webster; W W Nichols
Journal:  Circulation       Date:  1978-11       Impact factor: 29.690

6.  Long-term antianginal action of verapamil assessed with quantitated serial treadmill stress testing.

Authors:  B Subramanian; M Bowles; A Lahiri; A B Davies; E B Raftery
Journal:  Am J Cardiol       Date:  1981-09       Impact factor: 2.778

7.  Treatment of angina at rest with nifedipine: a short-term controlled study.

Authors:  M Previtali; J A Salerno; L Tavazzi; M Ray; A Medici; M Chimienti; G Specchia; P Bobba
Journal:  Am J Cardiol       Date:  1980-04       Impact factor: 2.778

8.  Nifedipine therapy for coronary-artery spasm. Experience in 127 patients.

Authors:  E Antman; J Muller; S Goldberg; R MacAlpin; M Rubenfire; B Tabatznik; C S Liang; F Heupler; S Achuff; N Reichek; E Geltman; N Z Kerin; R K Neff; E Braunwald
Journal:  N Engl J Med       Date:  1980-06-05       Impact factor: 91.245

9.  Effect of diltiazem in patients with variant angina: a randomized double-blind trial.

Authors:  C J Pepine; R L Feldman; J Whittle; R C Curry; C R Conti
Journal:  Am Heart J       Date:  1981-06       Impact factor: 4.749

10.  Verapamil in chronic stable angina. A controlled study with computerized multistage treadmill exercise.

Authors:  V B Subramanian; A Lahiri; R Paramasivan; E B Raftery
Journal:  Lancet       Date:  1980-04-19       Impact factor: 79.321

View more
  3 in total

Review 1.  The importance of stress-induced cardiac wall motion abnormalities in the evaluation of drug intervention.

Authors:  S Iliceto; C Caiati; F Tota; P Rizzon
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 2.  Increased coronary tone in exertional angina: the beneficial effects of calcium antagonists.

Authors:  G Specchia; D Ardissino; S Ghio; P Barberis; M L Colombo; S De Servi
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 3.  Gallopamil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in ischaemic heart disease.

Authors:  R N Brogden; P Benfield
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.